Tubulin inhibitors in non-small cell lung cancer: looking back and forward

References

• Nogales E. Structural insights into microtubule function. Annu Rev Biophys Biomol Struct 2001; 30:397–420.
   PubMedGoogle Scholar
• Rasco DW. Looking beyond surveillance, epidemiology and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529–1535.
   PubMed Web of Science ®Google Scholar
• Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65–71.
   PubMedGoogle Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253–265.
   PubMed Web of Science ®Google Scholar
• Lobert S, Vulevic B, Correia JJ et al. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996;35:6806–6814.
   PubMed Web of Science ®Google Scholar
• Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1–17.
   PubMedGoogle Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325–2333.
   PubMed Web of Science ®Google Scholar
• Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201212.
   Google Scholar
• Sève P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 2005;4(12):2001–2007.
   PubMed Web of Science ®Google Scholar
• Mani S, Swami U. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. Drugs Today (Barc). 2010;46(9):641–653.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086–1095.
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM, et al. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060–2069 (2002).
   PubMed Web of Science ®Google Scholar
• Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007;7(6):566–581.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res. 2002;11(1):103–118.
   PubMedGoogle Scholar
• Tozer GM, Kanthou C, Parkins C et al. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83, 21–38 (2002).
   PubMed Web of Science ®Google Scholar
• André N, Carré M, Pasquier E Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–431.
   PubMed Web of Science ®Google Scholar
• Pfannenstiel LW, Lam SS, Emens LA, et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 2010;263:79–87. 45.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor activity of a granulocyte-macrophage-colony stimulating factor-secreting whole-cell vaccine in HER-2/neu tolerized mice. Cancer Res 2001; 61:3689–3697.
   PubMed Web of Science ®Google Scholar
• Gerzon K. Anticancer agents based on natural product models. Cassady JM, Douros JD, editor. New York: Academic; 1980. p. 271–317.
   Google Scholar
• Karminsky N, Merimsky O, Kovner F et al. Vinorelbine-related acute cardiopulmonary toxicity. Cancer Chemother Pharmacol. 1999;43(2):180–182.
   PubMed Web of Science ®Google Scholar
• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325–2327.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Muggia FM, Alving CR et al. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst (1998) 90:300–306.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007;2(4):415–423.
   PubMed Web of Science ®Google Scholar
• Minshall RD, Tiruppathi C, Vogel SM, et al. Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol. 2002;117(2):105–112. 16.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared to cremophorbased paclitaxel. Clin Cancer Res. 2006;12(4):1317–1324.
   PubMed Web of Science ®Google Scholar
• Gottesman MM Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615–627.
   PubMed Web of Science ®Google Scholar
• Vasile E, Tibaldi C, Leon GL, et al. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients. J Cancer Res Clin Oncol. 2015;141(7):1189–1194.
   PubMed Web of Science ®Google Scholar
• Lu Q, Luduena RF In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of αβII, αβIII, and αβIV tubulin dimers in the absence of microtubuleassociated proteins. J Biol Chem 1994;269:2041–2047.
   PubMed Web of Science ®Google Scholar
• Monzo M, Rosell R, Sanchez JJ et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17(6):1786–1793.
   PubMed Web of Science ®Google Scholar
• Kamath K, Wilson L, Cabral F, et al. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005;280:12902–12907.
   PubMed Web of Science ®Google Scholar
• Seve P, Isaac S, Tredan O, et al. Expression of class III {β}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481–5486.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III β tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92:E25–30.
   PubMedGoogle Scholar
• Sève P, Dumontet C. Is class III beta tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008; 9 (2):168–175.
   PubMed Web of Science ®Google Scholar
• Koh Y, Jang B, Han SW, Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 2010;5(3):320–325.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Levallet G, Bergot E. et al. Evaluation of class III beta-tubulin (bTubIII) expression as a prognostic marker in patients with resectable non-small cell lung cancer (NSCLC) treated by perioperative chemotherapy (CT) in the phase III trial IFCT-0002 ( abstract 2009 ASCO annual meeting).
   Google Scholar
• Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–360.
   PubMed Web of Science ®Google Scholar
• Sève P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 2007;13(3):994–999.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Ruan L, Zheng LM, et al. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2012;77(1):9–15.
   PubMed Web of Science ®Google Scholar
• Yang YL, Luo XP, Xian L et al. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. PLoS One. 2014;9(4):e93997.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Schneider CP, Tsai CM, et al. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. J Clin Oncol. 2013;31(16):1990–1996.
   PubMed Web of Science ®Google Scholar
• Shao H, Tang H, Salavaggione OE, et al. Improved response to nab paclitaxel compared to cremophor solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in NSCLC. J Thorac Oncol 2011;6(6):998–1005.
   PubMed Web of Science ®Google Scholar
• Bertino EM, Williams TM, Nana-Sinkam SP Stromal caveolin-1 Is associated with response and survival in a phase II trial of nab-paclitaxel with carboplatin for advanced NSCLC patients. Clin Lung Cancer. 2015;16(6):466–474.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Plaza C, Musteanu M et al. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res. 2015;21(21):4811–4818.
   PubMed Web of Science ®Google Scholar
• Hersh EM, Del Vecchio M, Brown MP et al. A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol. 2015;26(11):2267–2274.
   PubMed Web of Science ®Google Scholar
• Ho CC, Kuo SH, Huang PH, et al. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59(1):105–110.
   PubMed Web of Science ®Google Scholar
• Kanakkanthara A, Miller JH MicroRNAs: novel mediators of resistance to microtubule-targeting agents Cancer Treat Rev. 2013;39(2):161–170.
   PubMed Web of Science ®Google Scholar
• Catuogno S, Cerchia L, Romano G miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis Oncogene. 2013;32(3):341–351.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Han Y et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010;55(9):2545–2551.
   PubMed Web of Science ®Google Scholar
• Cochrane DR, Spoelstra NS, Howe EN et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009;8(5):1055–1066.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang H, Liu J et al. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 2013; 372 (1–2): 35–45.
   PubMed Web of Science ®Google Scholar
• Chen D, Huang J, Zhang K et al, MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer. 2014;50(17):3050–3067.
   PubMed Web of Science ®Google Scholar
• Yin S, Bhattacharya R, Cabral F et al. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010;9(2):327–335.
   PubMed Web of Science ®Google Scholar
• Ganguly A, Cabral F. New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta. 2011;1816(2):164–171.
   PubMed Web of Science ®Google Scholar
• Shen W, Pang H, Liu J et al. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res. 2014;22(1):47–55.
   PubMed Web of Science ®Google Scholar
• Wender P, Galliher W, Bhat N et al. Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecol Oncol. 2012;126(1):118–123.
   Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–3559.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–1277
   PubMed Web of Science ®Google Scholar
• Sörenson S, Glimelius B, Nygren P, et al. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol. 2001; 40 (2–3): 327–339.
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27(3):145–157.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–727.
   PubMed Web of Science ®Google Scholar
• Crawford J, O’Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared to fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 1996;14(10):2774–2784.
   PubMed Web of Science ®Google Scholar
• Gridelli C The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001;6 Suppl 1:4–7.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C,et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95(5):362–372.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared to vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24(22):3657–3663.
   PubMed Web of Science ®Google Scholar
• Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998;16(7):2459–2465
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994;12(2):360–367.
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–1531.
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13(1):33–42
   PubMed Web of Science ®Google Scholar
• Variol P, Nguyen L, Tranchand B, et al. A simultaneous oral/ intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 2002; 58 (7): 467–476
   PubMed Web of Science ®Google Scholar
• Jassem J, Ramlau R, Karnicka-Mlodkowska H, et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001; 12 (10): 1375–1381
   PubMed Web of Science ®Google Scholar
• Kontopodis E, Hatzidaki D, Varthalitis I,et al. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J Chemother. 2013;25(1):49–55.
   PubMed Web of Science ®Google Scholar
• Camerini A, Puccetti C, Donati S et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15:359.
   PubMed Web of Science ®Google Scholar
• Katsaounis P, Kotsakis A, Agelaki S et al. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) Cancer Chemother Pharmacol. 2015; 75(4):821–827.
   PubMed Web of Science ®Google Scholar
• Fløtten Ø, Grønberg BH, Bremnes R, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012;107(3):442–447.
   PubMed Web of Science ®Google Scholar
• Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12(6):1232–1237.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103.
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354–2362.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22 (9): 1589–1597.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P,et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared to delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591–598
   PubMed Web of Science ®Google Scholar
• Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006;32(8):583–587.
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253–263.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155.
   PubMed Web of Science ®Google Scholar
• Di Maio M1, Perrone F, Chiodini Pet al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared to once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(11):1377–1382.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Ardavanis A, Agelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol. 2004;22(13):2602–2609.
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016–3024
   PubMed Web of Science ®Google Scholar
• Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004;22(2):254–261.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Laporte S, Fossella F, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol. 2007;2(10):939–946.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Androulakis N, Kotsakis A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008;59(1):57–63.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A,et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357(9267):1478–1484.
   PubMed Web of Science ®Google Scholar
• Rigas J, Dragnev K, Kerry M et al. Survival equivalence of nonplatinum-based and latinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC): the results of a multicenter internet-based phase III randomized study (D0112) (abstract) Lung Cancer. 2005;49:S35.
   Google Scholar
• Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23(13):2937–2945.
   PubMed Web of Science ®Google Scholar
• D’Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–2936.
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon JE 2nd, Ma M, et al. Adjuvant paclitaxel plus carboplatin compared to observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043
   PubMed Web of Science ®Google Scholar
• Chang WJ, Sun JM, Lee JY et al A retrospective comparison of adjuvant chemotherapeutic regimen for non small cell lung cancer: paclitaxel and carboplatin versus Vinorelbine plus cisplatin. Lung Cancer 2014: 84 (1):51–55
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–857.
   PubMed Web of Science ®Google Scholar
• Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92(13):1074–1080
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18(19):3390–3399.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Splinter TA, Debruyne C et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998;16(6):2133–2141.
   PubMed Web of Science ®Google Scholar
• Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005;16(7):1069–1075.
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19(13):3210–3218.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol. 2002;20(21):4285–4291.
   PubMed Web of Science ®Google Scholar
• Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18(3):623–631.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE 2nd, Ma Let al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23(1):190–196.
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared to monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–1088.
   PubMed Web of Science ®Google Scholar
• Smit EF, Van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol. 2003;21(21):3909–3917.
   PubMed Web of Science ®Google Scholar
• Kosmidis P, Mylonakis N, Nicolaides C,et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002;20(17):3578–3585.
   PubMed Web of Science ®Google Scholar
• Grossi F, Aita M, Defferrari C, et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist. 2009;14(5):497–510.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–2062.
   PubMed Web of Science ®Google Scholar
• Spira AI, Iannotti NO, Savin MA,et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):31–38.
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Tsao-Wei DD, Groshen S, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012;7(3):574–578.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007;25(23):3448–3455.
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Mellemgaard A, Sanchez JM, et al. Activity of patupilone in advanced or metastatic non-small cell lung cancer: a phase II study [abstract]. Ann Oncol 2008; 19(8S):296P
   Google Scholar
• Gatzemeier U, Von Pawel J, Eschbach C, et al. 6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. EJC Suppl 2007;5(4):378
   Web of Science ®Google Scholar
• Spigel DR, Anthony Greco F, Waterhouse DM, et al. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer. 2012;78(1):70–75.
   PubMed Web of Science ®Google Scholar
• Mok TS, Geater SL, Iannotti N, et al. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Ann Oncol. 2014;25(8):1578–1584.
   PubMed Web of Science ®Google Scholar
• Eberhardt WE, De Ruysscher D, Weder W, et al. 2nd ESMO conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–1588
   PubMed Web of Science ®Google Scholar
• Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999;9:12–26.
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck JP, Kramer GW, Van Schil PE, Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(6):442–450.
   PubMedGoogle Scholar
• Van Meerbeeck JP, Kramer G, Van Schil P, et al. Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC): an analysis of different regimens used in EORTC 08941. Lung Cancer 2003;41:S79–80
   Google Scholar
• Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–386.
   PubMed Web of Science ®Google Scholar
• Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–2190.
   PubMed Web of Science ®Google Scholar
• Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386(9998):1049–1056.
   PubMed Web of Science ®Google Scholar
• Wang L, Wu S, Ou G, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2012;77(1):89–96.
   PubMed Web of Science ®Google Scholar
• Santana-Davila R, Devisetty K, Szabo A, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol. 2015;33(6):567–574.
   PubMed Web of Science ®Google Scholar
• Lammers PE, Lu B, Horn L, et al. nab-paclitaxel in combination with weekly carboplatin with concurrent radiotherapy in stage III non-small cell lung cancer. Oncologist. 2015;20(5):491–492
   PubMed Web of Science ®Google Scholar
• Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/ NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929–1937
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87–98
   PubMed Web of Science ®Google Scholar
• Huber RM, Engel-Riedel W, Kollmeier J, et al. GILT study: oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): final results of a phase (ph) III study. J Clin Oncol 2012; 30(Suppl):abstract7001. Presented at the 2012 ASCO Annual Meeting; 1 – 5 June 2012; Chicago, Illinois.
   Google Scholar
• Kollareddy M, Dzubak P, Zheleva D, et al. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152(1):27–33.27
   PubMed Web of Science ®Google Scholar
• Casaluce F, Sgambato A, Maione P, et al. Emerging mitotic inhibitors for non-small cell carcinoma. Expert Opin Emerg Drugs. 2013;18(1):97–10.
   PubMed Web of Science ®Google Scholar
• Komlodi-Pasztor E, Sackett D, Wilkerson J et al. Mitosis is not a key target of microtubule agents in patient tumors. Nat Clin Oncol 8, 244–250 (2011).
   PubMed Web of Science ®Google Scholar
• Anderson H, Hopwood R, Stephens R, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. Br J Cancer 2000;83:447–453.
   PubMed Web of Science ®Google Scholar
• Yana T, Takada M, Origasa H et al. New chemotherapy agent plus platinum for advanced non-small cell lung cancer: a meta-analysis. Proc Am Soc Clin Oncol 2002;21: 328a ( Abstr 1309).
   Google Scholar
• Baggstrom MQ, Stinchcombe TE, Fried DB et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007;2(9):845–853.
   PubMed Web of Science ®Google Scholar
• Jackson JR, Patrick D, Dar MM et al. Targeted anti-mitotic therapies: can w e improve on tubulin agents? Nat Rev Cancer. 2007;7(2):107–117.
   PubMed Web of Science ®Google Scholar
• Proia D, Sang J, He S et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 2012;30(6):2201–2209
   PubMed Web of Science ®Google Scholar
• Chi KN, HIgano C, Reeves J. A randomized phase III study comparing first line docetaxel and prednisone (DP) to DP plus custirsen in men wih metastatic castration resistant prostate cancer. Ann Oncol25(Supplement 4): iv255–iv279, 2014 doi:10.1093/annonc/mdu336.3
   Google Scholar
• O’Connell BC, O’Callaghan K, Tillotson B, et al. HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer. PLoS One. 2014;9(12):e115228.
   Google Scholar
• Sinnott R, Winters L, Larson B, Mechanisms promoting escape from mitotic stress-induced tumor cell death. Cancer Res. 2014;74(14):3857–3869.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Goss GD, Andric GZ. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin Oncol 2013;31(suppl; abstr CRA8007). Presented at the 2013 ASCO Annual Meeting; 2013 May 31-Jun 4; Chicago (IL).
   Google Scholar
• Scagliotti G, Von Pawel J, Novello S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(24):2667–2674.
   PubMed Web of Science ®Google Scholar
• Basilico C, Pennacchietti S, Vigna E, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res. 2013;19(9):23811
   Web of Science ®Google Scholar
• Metronomic vinorelbine and bevacizumab in patients with non small cell lung cancer [Internet]. [cited 2015 Dec 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT0075517
   Google Scholar
• Study of combination of metronomic oral vinorelbine and sorafenib in patients with advanced non-small cell lung cancer [Internet]. [cited 2015 Dec 1]. Available from: http://clinicaltrials.gov
   Google Scholar
• Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood. 2005;106(9):3058–3061.
   PubMed Web of Science ®Google Scholar